These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 17244765)

  • 1. Pramipexole and Selegiline Combination Therapy in a Case of Treatment-Resistant Depression.
    Moirand R; Galvao F; Dondé C
    J Clin Psychopharmacol; 2019; 39(6):684-685. PubMed ID: 31688405
    [No Abstract]   [Full Text] [Related]  

  • 2. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.
    Boyce RD; Handler SM; Karp JF; Hanlon JT
    Am J Geriatr Pharmacother; 2012 Apr; 10(2):139-50. PubMed ID: 22285509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.
    Pilgrim JL; Gerostamoulos D; Drummer OH
    Forensic Sci Med Pathol; 2011 Jun; 7(2):162-84. PubMed ID: 21052868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal selegiline for the treatment of major depressive disorder.
    Lee KC; Chen JJ
    Neuropsychiatr Dis Treat; 2007; 3(5):527-37. PubMed ID: 19300583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
    Azzaro AJ; VanDenBerg CM; Ziemniak J; Kemper EM; Blob LF; Campbell BJ
    J Clin Pharmacol; 2007 Aug; 47(8):978-90. PubMed ID: 17554106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
    Tobin M
    Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
    [No Abstract]   [Full Text] [Related]  

  • 8. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of adverse interactions between concomitantly administered selegiline and citalopram.
    Laine K; Anttila M; Heinonen E; Helminen A; Huupponen R; Mäki-Ikola O; Reinikainen K; Scheinin M
    Clin Neuropharmacol; 1997 Oct; 20(5):419-33. PubMed ID: 9331518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Feb; 47(2):146-58. PubMed ID: 17244765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selegiline transdermal system Somerset.
    Mahmood I
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transdermal selegiline.
    Patkar AA; Pae CU; Zarzar M
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.